Self-aligning smart microscope achieves unprecedented resolution 23 April 2020 | By Hannah Balfour (Drug Target Review) The developers of the ultra-precise single-molecule microscope demonstrated it can resolve interactions between molecules within living cells and is compatible with existing microscopes.
Researchers identify lead compounds for treatment of telomere diseases 23 April 2020 | By Victoria Rees (Drug Target Review) Researchers investigating telomere dieases such as dyskeratosis congenita have found lead compounds that reverse cellular ageing in mouse models of the condition.
Fundamental molecular research underpins our ability to combat COVD-19, says article 23 April 2020 | By Hannah Balfour (Drug Target Review) Ali Shilatifard’s article explains how investment in institutes performing molecular research is essential, as it is the foundation for all attempts to combat COVID-19 and other future pandemics.
Lead SARS-CoV-2 inhibitor compound identified by researchers to treat COVID-19 23 April 2020 | By Victoria Rees (Drug Target Review) Researchers have found a lead compound which they say inhibits SARS-CoV-2 viral replication and demonstrates good pharmacokinetic activity in vivo.
Could T-cell immunotherapy be the answer to COVID-19? 22 April 2020 | By Victoria Rees (Drug Target Review) Scientists from Singapore have argued that T-cell immunotherapy can be used to combat a range of infectious diseases, including COVID-19.
Experiments with Marburg virus reveal novel antibody protective mechanisms 22 April 2020 | By Hannah Balfour (Drug Target Review) Researchers discovered the monoclonal antibodies of a convalescent Marburg infection patient bound to the glycoprotein and combatted infection in two novel ways.
COVID-19 research indicates SARS-CoV-2 exploits immune defences to drive infection 22 April 2020 | By Hannah Balfour (Drug Target Review) A new study has revealed that less than 10 percent of respiratory and intestinal cells are susceptible to SARS-CoV-2 infection and expression of ACE2 receptors is driven by the body's immune response.
Researchers develop open access database on macrolactones 22 April 2020 | By Victoria Rees (Drug Target Review) A group of researchers has created a free library of 14,000 known macrolactones for other scientists to use in drug development.
Novel antibody treatment for OCD demonstrates efficacy in mice 22 April 2020 | By Victoria Rees (Drug Target Review) Researchers who administered an antibody to neutralise an OCD-associated protein in mice found it reduced their anxious behaviours.
Glycomimetics could prevent COVID-19 from infecting human cells 21 April 2020 | By Hannah Balfour (Drug Target Review) Glycomimetics, a novel class of antivirals, prevented influenza, herpes viruses and papillomaviruses from infecting cells in animal models and could show similar efficacy against COVID-19.
£280 million donated for COVID-19 research in three months 21 April 2020 | By Victoria Rees (Drug Target Review) A study has shown that the COVID-19 pandemic has resulted in a high level of research donations, making the condition the third most funded disease on average by year.
High-throughput protocol for producing tetramer assay probes used to investigate COVID-19 21 April 2020 | By Hannah Balfour (Drug Target Review) The developers of a novel method to create immunological assay probes for screening T cells has leveraged their new protocol against COVID-19.
New label-free microscopy method enables imaging inside living cells 21 April 2020 | By Victoria Rees (Drug Target Review) By combining quantitative phase microscopy and molecular vibrational imaging, researchers have created a new label-free microscopy technique.
Binding site of drug compound and tumour suppressor protein revealed 21 April 2020 | By Victoria Rees (Drug Target Review) Using cyro-electron microscopy, researchers have imaged the binding site between a molecule and the tumour suppressor protein PP2A, enabling optimisation of the drug compound.
Nanobodies developed to image COVID-19 Spike protein 20 April 2020 | By Victoria Rees (Drug Target Review) Researchers in the UK have selected nanobodies that bind with high affinity to the Spike protein on the COVID-19 coronavirus, enabling stabilisation for imaging.
